Mandy Jackson

I am Managing Editor, US Commercial News, for the Citeline Commercial publication Scrip. Views expressed here are strictly my own.

[Renaissance Capital @IPOtweet]

Phase 1 immune system diseases biotech Attovia Therapeutics files for a $100 million IPO $ATTO $IPO #IPO https://t.co/qHPySLnz8M

[Renaissance Capital @IPOtweet]

Cardiovascular diseases biotech Braveheart Bio files for a $100 million IPO $BRVE $IPO #IPO https://t.co/dm1DWNTMur

[Mandy Jackson @ScripMandy]

@PharmaScrip @PharmaPinkSheet @INVIVOnow Hot off the presses, our Scrip/Pink Sheet/In Vivo #BIO2026 day 4 BIO Notebook. Enjoy! Now, time to rest! 😎🌴☀️ https://t.co/YOjlpgmYi7

[Mandy Jackson @ScripMandy]

The combined Scrip/Pink Sheet/In Vivo coverage of #BIO2026 from days 1 & 2 is free to read at @PharmaScrip and @PharmaPinkSheet. These daily notebooks include snapshots from interviews & panels at the meeting. https://t.co/z09q5XM39e

[Mandy Jackson @ScripMandy]

Here’s the @PharmaScrip @PharmaPinkSheet and @INVIVOnow free-to-read #BIO2026 day 3 BIO Notebook with insights from interviews and presentations at the meeting. Day 4 coverage still to come and more to follow in the coming days and weeks! https://t.co/DKSL4iN4KB

[Mandy Jackson @ScripMandy]

Thank you to #BIO2026 “Betting Bold: How Smart Deals Build Biotech" panelists Rigel's Joseph Lasaga, Innoviva's Austin Hackett, Ovid's Jeff Rona and Protara's Jesse Shefferman for a great conversation this afternoon and to our audience for listening in! $RIGL $INVA $TARA $OVID

[Mandy Jackson @ScripMandy]

Picked up my badge for the @IAmBiotech BIO International Convention and I’m looking forward to moderating a panel tomorrow at 3-4 p.m. “Betting Bold: How Smart Deals Build Biotech” with executives from $INVA $RIGL $OVID & $TARA https://t.co/4uKpw9ldyV

[Mandy Jackson @ScripMandy]

On Tuesday at 1:45-2:45 p.m. I’m talking deals at #BIO2026 again as I moderate “Building Value Through Strategic Pipeline Diversification” with dealmakers from $JNJ and @Boehringer and the CEO of $ZVRA https://t.co/ZfYjpvteNB

[Mandy Jackson @ScripMandy]

Picked up my badge for the @IAmBiotech BIO International Convention and I’m looking forward to moderating a panel tomorrow at 3-4 p.m. “Betting Bold: How Smart Deals Build Biotech” with executives from $INVA $RIGL $OVID & $TARA https://t.co/4uKpw9ldyV

[Mandy Jackson @ScripMandy]

Just imagine this flu outbreak on an aircraft carrier or submarine jam-packed with thousands of US Navy personnel. Vaccines save lives and make our military work as safely and efficiently as we need them to as we attempt to wind down a war in Iran.

[Jake Tapper 🦅 @jaketapper]

NYT: A major flu outbreak has sickened nearly 160 troops at Lackland Air Force Base in Texas weeks after Defense Secretary Hegseth announced that U.S. troops would no longer be required to be vaccinated for the flu, defense officials said.

https://t.co/fFIt8Mhyzg

[Mandy Jackson @ScripMandy]

Lucky no. 13 - Kardigan raised $400m tonight in its IPO, the 13th biopharma IPO in the US so far this year. $KARD https://t.co/gXNP6WA7eC

[Renaissance Capital @IPOtweet]

Cardiovascular diseases biotech Kardigan sets terms for $350 million IPO $KARD $IPO #IPO https://t.co/37R3lUBm1I

[Renaissance Capital @IPOtweet]

Cancer biotech Parabilis Medicines ups shares offered by 33% ahead of $600 million IPO $PBLS $IPO #IPO https://t.co/2pUtOsMv8T

[Mandy Jackson @ScripMandy]

FDA concerns about PRC2 complex inhibition & potential secondary hematologic malignancies, with both EZH2- & EED-targeting, due to Ipsen’s Tazverik, ended Fulcrum’s pociredir development & now there’s a partial hold on 2 Daiichi Sankyo valemetostat trials. https://t.co/TA9rbN5cID

[Renaissance Capital @IPOtweet]

Cancer biotech Parabilis Medicines sets terms for $450 million IPO $PBLS $IPO #IPO https://t.co/G7FchwJhKw

[Sue Sutter @PinkSheetSutter]

SCOOP: $AMGN Fights @US_FDA On Tavneos Withdrawal Over Efficacy, Data Integrity Concerns https://t.co/rdaY0OD8Wo

[Mandy Jackson @ScripMandy]

This is some of the most valuable hantavirus information I’ve seen yet. And important to see in a region with many thousands of cruise ship visitors annually.

[SanDiegoCounty @SanDiegoCounty]

Hearing a lot about Hantavirus lately? While locally and in California, we don't see the Andes virus you're hearing about in the news, we monitor regularly for the Sin Nombre virus which does not spread person to person. More: https://t.co/WbLwvAnjdQ

[Renaissance Capital @IPOtweet]

Coagulation disorder biotech Hemab Therapeutics Holdings sets terms for $200 million IPO, pricing this week $COAG $IPO #IPO https://t.co/9kPm1ELvlM

[Mandy Jackson @ScripMandy]

Three $200m biotech IPOs expected to launch this week: Seaport, Avalyn, Hemab

[Renaissance Capital @IPOtweet]

US IPO Week Ahead: Biotechs, mining, and Bill Ackman deals set to debut $AVLN $COAG $SPTX $SBMT $PS $IPO #IPO https://t.co/wbf7Cn5DFg

[Renaissance Capital @IPOtweet]

Neuropsychiatric therapeutics Seaport Therapeutics sets terms for $201 million IPO, pricing this week $SPTX $IPO #IPO https://t.co/xWKAGymX0a